2025-05-22-Jefferies-瑞普利姆集团（REPL）_2025年第一季度生物制品许可申请审查和处方药用户费用法案按时推进_启动准备工作正在进行_10页_2mb

Replimune Group Equity Research Summary

Key Highlights

• Analyst Rating: BUY
• Current Price: $8.46
• Price Target: $31.00 (+266%)
• PDUFA Date: July 22, 2025 for RP1 submission in aPD1-refractory melanoma

Clinical Progress

• Completed FDA manufacturing inspections and late-cycle review ahead of PDUFA date.
• RP1 confirmatory trial is on track and does not affect PDUFA timeline.
• Enrollment ongoing in >100 global sites for adjuvant therapy trial with cemiplimab in 1L CSCC.

Commercial Preparation

• Built commercial infrastructure, hired teams, established distribution channels.
• First-year target market: ~13,000 US patients, ~80% eligible for RP1.
• Key accounts identified (~350 hospitals): outreach planned to reach ~80% of eligible patients.
• Utilizes next-day outpatient administration and reimbursement codes for affordability.

Financials

• Cash and equivalents: $483.8M as of Q1 2025.
• Cash runway extends into 4Q 2026, sufficient for RP1/ RP2 commercialization.

Investment Thesis

• Potential Peak Sales: $1.2B–$1.5B for RP1 in aPD1-refractory melanoma.
• Platform Value: Valued at up to $200M with potential for broad applicability of RP2.

Risks

• Regulatory: no communication changes with FDA anticipated.
• Commercial: payer coverage, competition from established therapies.

Company Overview

• Oncolytic virotherapy developer for melanoma, CSCC, and other tumors.
• RP2 pipeline for nonskin tumors shows promise.

See Full Report for pipeline updates and detailed analyst disclosures.